EASD 2020 Highlights Podcast

 

Dr Rachel Giles guides us through 6 abstracts from the 56th EASD Annual Meeting:

1. Ertugliflozin offers some kidney protection - Cherney et al.


2. Empagliflozin significantly reduces CV and renal risk - Packer et al.


3. Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes - Valcarce et al.


4. Diabetes still goes unnoticed, resulting in delayed diagnosis - Young et al.


5. Once-weekly insulin is a promising treatment option - Rosenstock et al.


6. Intermittent fasting: consuming fewer calories but in a different way - Varady et al.

© 2023 The Author(s). Published by Medicom Medical Publishers.
User license: Creative Commons Attribution – NonCommercial (CC BY-NC 4.0)

Posted on 8 December, 202028 January, 2021